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Acid-related disorders include not only reflux esophagitis and peptic ulcer, but
also a subset of patients with endoscopy-negative dyspepsia. The management
strategy differs between these diseases and therefore a precise diagnosis is
important. The unaided clinical diagnosis is of limited value in patients with
pain or discomfort in the upper abdomen, and endoscopy is therefore an impor-
tant and cost-effective diagnostic tool.
Duodenal ulcer is caused by an interplay between gastric acid and Helicobacter
pylori. The treatment is aimed at rapid symptom relief and healing and at the
same time eradication of H. pylori. At present the best choice is the combina-
tion ofa proton pump inhibitor and two effective antimicrobial drugs, e.g., clar-
ithromycin and metronidazole. The proton pump inhibitor has dual effect in this
combination itprovides optimal symptom reliefand healing, and it increases the
anti-H. pylori-effect of the antimicrobial drugs. The risk of reinfection varies
geographically; in Europe it is around 1 percent per year, and cure of the infec-
tion provides long-term, maybe life-long, cure of the ulcer disease. Some gas-
tric ulcers are not H. pylori-related and the treatment strategy therefore includes
a diagnostic test for this infection. Ifpositive, treatment is similarto that in duo-
denal ulcer, while H. pylori-negative gastric ulcer patients are treated with anti-
secretory drugs alone.
Reflux esophagitis correlates with the degree ofacid exposure to the esophagus,
and intensive acid inhibition is the most effective non-surgical therapy. In most
cases the disease is chronic and needs continuous long-term therapy to prevent
relapse. A staged reduction in dosage of the acid inhibitory drug may be
attempted when the esophagitis is healed and the patient has become symptom
free, but full dose therapy is often needed.
Patients with endoscopy-negative dyspepsia are a heterogenous group and a
more precise identification of the cause of the symptoms is a prerequisite for
rational treatment. Empiric treatment can be tried in patients without alarm
symptoms like bleeding or a palpable abdominal mass, and often an acid
inhibitory drug is used. A more precise identification ofthose patients who have
acid-related symptoms is possible using placebo controlled single-subject trials
with an effective acid inhibitory drug, but in daily routine these drugs are sim-
ply given for a short period oftime, and in case symptomatic reliefis observed,
the symptoms may be regarded as being acid-related and treated accordingly.
INTRODUCTION
The term acid-related disorder refers traditionally to two distinct diseases: peptic
ulcer and reflux esophagitis. Recent studies ofpatients with endoscopy-negative dyspep-
sia have, however, clearly shown that gastric acid may cause pain and discomfort also in
patients with no visible mucosal lesion in the esophagus, stomach or duodenum [1-4]. In
some of these cases, an abnormal high acid exposure to the esophagus can be demon-
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strated, but in many cases the results of pH-metry falls within the normal range, even in
the group ofpatients with heartburn-predominant dyspepsia [1, 3].
The subgroups ofpatients with pain or discomfort in the upper abdomen are listed in
Table 1, and it should be emphasized that the role ofHelicobacterpylori-gastritis in dys-
pepsia is still unknown .
A rational management strategy presupposes a diagnostic strategy. Considering the
NIH recommendations that routine antimicrobial therapy against H. pylori should be
restricted to those patients with an H. pylori-related peptic ulcer [5], a precise diagnosis
is important, now more than ever. Unfortunately, unaided clinical diagnosis based on
Table 1. Subsets ofpatients with pain or discomfort in the upper abdomen.
Acid related:
Peptic ulcer disease
Gastro-esophageal reflux disease
Reflux esophagitis
Endoscopy-negative reflux disease with abnormal acid exposure
Endoscopy-negative reflux disease with normal acid exposure
Endoscopy-negative, non-reflux dyspepsia?
H. pylori related:
Peptic ulcer disease
Gastric cancer
Endoscopy-negative dyspepsia?
Dysmotility related:
Gastro-esophageal reflux disease
Endoscopy-negative, non-reflux dyspepsia?
symptoms and demographic data is oflimited value in patients with pain or discomfort in
the upper abdomen. Every second dyspeptic patient with endoscopically confirmed active
peptic ulcer is missed by clinical diagnosis even in situations with a high susceptibility of
ulcer leading to a poor predictive value of that clinical diagnosis (Table 2) [6].
Furthermore, approximately one-third of patients with organic disease are misclassified
as having functional dyspepsia [6-8]. Even patients with malignant disease can be hard to
diagnose clinically, apart from those with advanced disease in whom the exact diagnosis
will have no therapeutic implications. Fortunately, gastric and esophageal cancers are rare
Table 2. Validity of clinical judgement as predictor of peptic ulcer: results from a clinical
experiment in 1024 dyspeptic patients referred for a diagnostic endoscopy. Adapted from [8].
Endoscopy
Ulcer No ulcer Total
Clinical Ulcer 76 151 227
judgement No ulcer 71 726 797
Total 147 877 1024
20Rune and Bytzer: Management ofacid-related disorders
findings in dyspeptic patients, and malignancy is found almost exclusively in older
patients. As a consequence most authorities have recommended that endoscopy be
reserved for those older than 40-45 years of age with new onset of dyspeptic symptoms
[9]. On the other hand, recent studies have demonstrated the superiority of prompt
endoscopy compared to a strategy based on empirical H2-blocker treatment, both in terms
of patient satisfaction, health care related costs [10, 11], and detection rates ofearly gas-
tric cancer [12]. This view has been challenged by others [13-16], and particularly the
possibility ofscreening dyspeptic patients for endoscopy according to their H. pylori sta-
tus may be promising [16]. However, we still need randomized clinical trials in unselect-
ed patients to substantiate the suggestions ofaclinical and economic benefit by using this
strategy. These studies are under way and will be reported in the near future.
The importance of a precise diagnosis for obtaining optimal therapeutic gain should
be balanced against cost and availability of endoscopy, and the strategy therefore varies
geographically as well as with time. This decision is a complex one and it should encom-
pass economic and clinical considerations as well as patient factors like anxiety, distress,
and preferences.
MANAGEMENT STRATEGY IN PEPTIC ULCER DISEASE
Duodenal ulcer
The most important novelty in gastroenterology during the recent years is the dis-
covery ofH. pylori and its role in peptic ulcer disease. It is now well documented that the
annual relapse rate of duodenal ulcer is reduced to a few percent after cure of H. pylori
infection [17], and eradication of H. pylori has therefore become a primary goal in duo-
denal ulcer disease. When a duodenal ulcer is diagnosed the treatment strategy should be
aimed at providing rapid pain relief, rapid healing, and at the same time cure ofthe infec-
tion. Although prostaglandin analogues are effective in healing duodenal ulcers, they show
low efficacy with regard to ulcer pain relief and high incidence ofdiarrhea [18, 19], and a
combination of a proton pump inhibitor and two antimicrobial drugs seems the optimal
choice at present, because effective acid inhibition not only gives maximal symptom relief
and healing, but also improves the anti-Helicobacter efficacy ofantimicrobial drugs [20].
Alternative treatment regimens include the original triple therapy ofbismuth, tetracycline,
and metronidazole and combinations of H2-blockers with two antibiotics. The original
triple therapy is less expensive but may have significant compliance problems and a high
incidence of side-effects. The duration of the antimicrobial regimen is one to two weeks,
and if the patient is free ofulcer symptoms at this time, also the acid inhibitory drug may
be stopped since the ulcer healing process will continue, provided the infection is cured
[21]. There is no reason to perform repeat endoscopy unless the patient continues to have
symptoms, or in case the ulcer was complicated with bleeding. In that case, the anti-secre-
tory treatment should be prolonged some weeks and endoscopy repeated to ensure ulcer
healing. It is important to emphasize that eradication of H. pylori also reduce recurrence
of bleeding ulcers.
It is debated whether or not a diagnostic test for H. pylori is needed when a duodenal
ulcer is diagnosed. The very high prevalence (greater than 90 percent) ofH. pylori infec-
tion in this disease, together with a considerable risk of false negative results of the biop-
sy-based tests are the arguments for not performing a diagnostic test. The argument for
testing is to avoid unnecessary antimicrobial treatment in H. pylori-negative patients. The
battery of diagnostic tests of H. pylori infection differ with respect to sensitivity, speci-
ficity, invasiveness, cost, and to what additional information they provide, such as degree
ofgastritis and susceptibility ofthe bacteria to antimicrobial drugs. There is no "gold stan-
dard" for the detection of the bacterium, and the choice of test depends upon the clinical
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situation. Both non-invasive urea breath testing and serology as well as biopsy-based his-
tology and rapid urease tests are reliable indicators ofH. pylori infection and a single test
is sufficient [22]. In clinical situations where an endoscopy is indicated for other reasons
a biopsy-based test is convenient, and in most cases a rapid urease test is the method of
choice. Histology should be chosen when a histopathological assessment is wanted, for
instance to exclude malignancy in a gastric ulcer. In cases of treatment failure biopsies
should be cultured and antibiotic sensitivity profiles should guide further therapy. In most
patients the clinical response is sufficient evidence of treatment success. Iftreatment fail-
ure is suspected urea breath tests, when available, and not serology should be used to doc-
ument eradication. To avoid false negative results the breath test should be performed 4-6
weeks after end of treatment.
Previously verified duodenal ulcer disease and recurrence ofdyspeptic symptoms
This patient will not need repeated endoscopy to confirm relapse ofa duodenal ulcer,
provided the symptoms are "ulcer like" and there are no additional alarm symptoms. It is
very likely that the patient will benefit from anti-H. pylori therapy, and it is reasonable to
confirm H. pylori infection with a non-invasive test, e.g., urea breath test or serology. If
the patient is infected, eradication therapy should be given, also in case the patient is tak-
ing aspirin or NSAIDsb, since it is much more likely that the duodenal ulcer is H. pylori-
related and not NSAID-related, and there is no test which can determine whether an ulcer
is caused by NSAIDs.
Gastric ulcer
The treatment strategy when a gastric ulcer is found differs for several reasons from
that recommended in patients with a duodenal ulcer. There is a lower prevalence of H.
pylori infection in patients with gastric ulcer and therefore a diagnostic test should be car-
ried out, most convenient as a biopsy-based test at the time ofendoscopy. If the patient is
infected eradication therapy is given, including an effective acid inhibitory drug, which
should be continued for 4 weeks after the antibiotics are stopped. The reason for this, is
that the gastric ulcer might not be H. pylori-related and consequently needs the usual time
for healing with an antisecretory agent.
In case the patient is not infected, monotherapy with an antisecretory drug is given.
Repeat endoscopy is recommended in gastric ulcer until complete healing to exclude
malignancy [23]. The optimal time for this second endoscopy is shortly after the ulcer is
expected to be healed, and therefore it depends on the size of ulcer. Small gastric ulcers
heal within 4 weeks, while larger ulcers may take 6-8 weeks [24].
In patients who are NSAID-users, long-term treatment with a mucosal protective
agent or an antisecretory drug may be useful as prophylaxis against recurrence of the
ulcer, in case the NSAID-therapy can not be discontinued.
Recurrence ofdyspeptic symptoms in patients with a previously diagnosed gastric ulcer
The recurrence rate ofgastric ulcers is lower than it is for duodenal ulcers, and when
the risk ofmalignancy is also taken into account, endoscopy is recommended in this case
to confirm ulcer recurrence and to exclude gastric cancer. In case a benign gastric ulcer is
found, it is relevant to test whether or not the patient is H. pylori infected, and a biopsy-
based test should be performed. If the patient is found positive eradication therapy should
be given, including an antisecretory drug.
MANAGEMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE
Symptoms of gastro-esophageal reflux are very common in the general population,
and also in primary and secondary care. The prevalence ofreflux symptoms was found to
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be around 37 percent in a study from NorthAmerica [25] and a study from Sweden report-
ed a six-month prevalence of 26 percent [26]. An estimated 25 percent of patients with
heartburn seek medical advice, while most patients are self-medicating with antacids,
alginates, or acid inhibitory drugs.
As shown in Table 1 only some patients with acid reflux have endoscopic esophagi-
tis, since some have abnormal acid exposure to the esophagus without visible mucosal
lesions, and some have reflux symptoms with esophageal pH monitoring within the nor-
mal range. Increasing severity of symptoms correlates with the duration of time with
esophageal pH above 4 [27] and symptom-related reflux episodes last longer than those
not perceived by the patient. Therefore acid contact time seems to be a contributing fac-
tor to esophageal sensitivity [28].
The rational treatment of reflux disease would be to improve the competence of the
lower esophageal sphincter, but surgery is still the only effective treatment in this respect.
Therefore acid suppressive drugs become the key-stone in the management of reflux, in
addition to lifestyle advice. Prokinetic drugs like cisapride modify esophageal function by
increasing lower esophageal sphincter pressure and the amplitude ofesophageal contrac-
tions. They promote gastric emptying by increasing antral contractions and enhancing
antro-duodenal coordination. Prokinetics can be used to control reflux symptoms, butthey
are less effective compared to proton pump inhibitors in healing the more severe grades
ofesophagitis [29], and the most satisfactory results in the treatment oferosive esophagi-
tis have been seen with proton pump inhibitors [30].
In most patients, gastro-esophageal reflux is a chronic disease, with rapid relapse
after withdrawal of treatment and with long lasting consequences for quality of life and
morbidity [31]. A recurrence rate about 80 percent during the first six months is a com-
mon finding [32], and therefore continuous long-term therapy is usually required. A
staged reduction in dosage of the acid inhibitory drug may be attempted when the
esophagitis is healed and the patient has become symptom free, but full dose therapy is
often necessary [33].
IDENTIFICATION OF PATIENTS WITH ENDOSCOPY-NEGATIVE
ACID-RELATED DYSPEPSIA
Patients presenting with dyspepsia are a heterogenous group and a more precise iden-
tification of the cause of the symptoms is a prerequisite for a rational treatment. When
endoscopy has found no visible abnormality in the esophagus, stomach, or duodenum,
empiric symptomatic treatment can be tried in patients without alarm symptoms. The
rationale forprescribing an acid inhibitor in this situation is, ofcourse, the assumption that
the symptoms are acid-related, but this is only the case in a subgroup of these patients.
Some symptoms such as heartburn are usually taken as a symptom of gastroesophageal
reflux, but the diagnostic value ofthe clinicaljudgement is generally low. A more precise
identification of those patients who have acid-related symptoms is possible using place-
bo-controlled single-subject trials with either an H2-receptor antagonist [34] or omepra-
zole [35], but in daily clinical routine these drugs are simply given for a short period of a
few weeks, and in case adequate symptom relief is obtained, the symptoms might be acid
related. It is important to keep in mind, though, the very high placebo response in these
patients, usually approaching 50-70 percent in most trials. Thus, the validity of the
response to acid inhibition is supported if the symptoms recur shortly after stop of treat-
ment, and especially if the successful response can be repeated.
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